6497 Aslan Pharmaceuticals

ASLAN Pharmaceuticals Submits Clinical Trial Authorisation Application for First in Man Studies for ASLAN004

ASLAN Pharmaceuticals Submits Clinical Trial Authorisation Application for First in Man Studies for ASLAN004

SINGAPORE, July 03, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT) (NASDAQ:ASLN), a clinical-stage biopharmaceutical company based in Asia developing novel therapeutics for global markets, today announced the submission of a clinical trial authorisation application with the Singapore Health Sciences Authority (HSA) to initiate a phase 1 trial of ASLAN004. The single ascending dose study will recruit healthy volunteers and the multiple ascending dose study will recruit patients with atopic dermatitis.

ASLAN004 is a fully human monoclonal antibody that targets the IL-13 receptor α1 subunit (IL-13Rα1) and potently inhibits interleukin 4 (IL-4) and interleukin 13 (IL-13). IL-4 and IL-13 are central to triggering symptoms of allergy in atopic dermatitis, such as redness and itching of the skin. By targeting IL-13Rα1, ASLAN004 has the potential to offer both a lower dose and dosing frequency than currently available treatments for atopic dermatitis which target the same pathways. ASLAN004’s selective binding may also offer a more favourable side effect profile.

Dr Carl Firth, CEO of ASLAN Pharmaceuticals, said: “We believe that ASLAN004 has the potential to be a best-in-class therapy, offering the potential for reduced injection frequency and greater convenience for patients than current treatment options for atopic dermatitis.”

Atopic dermatitis is the most common dermatological disease, affecting over 200 million patients worldwide1, characterised by red inflamed skin and severe daytime and night time itching, which can severely impact patients’ quality of life. Up to one-third of adult atopic dermatitis patients are considered moderate-to-severe2, for which currently available therapeutics are limited and management is challenging in the majority of cases.

Media and IR contacts

Emma Thompson

Spurwing Communications

Tel:

Email:  
Robert Uhl

Westwicke Partners

Tel:

Email:

About ASLAN004

ASLAN004 is a fully human monoclonal antibody that targets the IL-13 receptor α1 subunit, or IL-13Rα1, with potential to be a best-in-class therapy. ASLAN004 is currently in preclinical development. By targeting IL-13Rα1, ASLAN004 potently inhibits signalling of both interleukin 4, or IL-4, and interleukin 13, or IL-13. IL-4 and IL-13 are central to triggering symptoms of allergy in atopic dermatitis, such as redness and itching of the skin, as well as asthma symptoms such as shortness of breath, wheezing and coughing.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (ASLAN, 6497.TT) (NASDAQ:ASLN) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialisation, ASLAN is headquartered in Singapore and has offices in Taiwan and China. ASLAN’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. ASLAN’s partners include Array BioPharma, Bristol-Myers Squibb, Almirall and CSL. For additional information please visit .

_____________________________

1 Nutten, S. 2015. Atopic dermatitis: global epidemiology and risk factors

2 D’Erme AM, Romanelli M, Chiricozzi A. 2017. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy. Dove Press journal: Drug, Design and Therapy Vol 2017:11 p1473—1480

EN
03/07/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aslan Pharmaceuticals

 PRESS RELEASE

ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthc...

ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022 MENLO PARK, Calif. and SINGAPORE, April 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present at the 21st Annual Needham Virtual Healthcare Conference. The conference will be held virtually from April 11 to 14, 2022. Presentation details Date: Thursday, April 14, 2022Time: 10:15 - 10:55am ETFormat: Compa...

 PRESS RELEASE

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Re...

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement MENLO PARK, Calif. and SINGAPORE, April 01, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN) ("ASLAN" or the "Company"), announced today that on March 28, 2022, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the US$1.00 minimum bid price requirement under the Nasdaq Listing Rules (the "Listing Rules"). Based on the closing bid price of ...

 PRESS RELEASE

ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From...

ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting MENLO PARK, Calif. and SINGAPORE, March 28, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the oral presentation of data from the completed Phase 1b multiple-ascending-dose (MAD) study that established proof of concept for eblasakimab (ASLAN004) in moderate-to-sever...

 PRESS RELEASE

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financ...

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) underway with topline data expected in the first half of 2023New CMO appointed, adding senior global pharma experience to the leadership team Company maintains strong operating position with US$90.2 million in cash and cash equivalents as of December 31, 2021, runway through late 2023Replays available for company-hosted A4 KOL series on AD landscape; next event to be held in the second quarter ME...

 PRESS RELEASE

ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract o...

ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting - Topline data from the eblasakimab Phase 1b multiple-ascending-dose study will be presented during the “Late-breaking Research: Clinical Trials” session at the 2022 American Academy of Dermatology Annual Meeting on March 26 MENLO PARK, Calif. and SINGAPORE, March 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutica...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch